Literature DB >> 11574282

Gelatinase B: a tuner and amplifier of immune functions.

G Opdenakker1, P E Van den Steen, J Van Damme.   

Abstract

Gelatinase B (matrix metalloproteinase-9) is a secreted multidomain enzyme that is important for the remodeling of the extracellular matrix and the migration of normal and tumor cells. It cleaves denatured collagens (gelatins) and type IV collagen, which is present in basement membranes. In the immune system, this cleavage helps lymphocytes and other leukocytes to enter and leave the blood and lymph circulations. Gelatinase B also cleaves myelin basic protein and type II gelatins, and this clipping leads to remnant epitopes that generate autoimmunity, the so-called REGA model of autoimmunity. Recently, gelatinase B has been found to process cytokines and chemokines, resulting in skewed immune functions. Therefore, gelatinase B, often considered as a pure effector molecule, acts as a switch and catalyst in both innate and specific immunity, and constitutes a prototypic example of the regulation of immune functions by proteolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574282     DOI: 10.1016/s1471-4906(01)02023-3

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  116 in total

1.  Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1.

Authors:  Jennifer Vandooren; Benjamin Born; Inna Solomonov; Ewa Zajac; Radka Saldova; Michael Senske; Estefanía Ugarte-Berzal; Erik Martens; Philippe E Van den Steen; Jo Van Damme; Angeles Garcia-Pardo; Matheus Froeyen; Elena I Deryugina; James P Quigley; Søren K Moestrup; Pauline M Rudd; Irit Sagi; Ghislain Opdenakker
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

Review 2.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

3.  The thymus microenvironment in regulating thymocyte differentiation.

Authors:  Jacy Gameiro; Patrícia Nagib; Liana Verinaud
Journal:  Cell Adh Migr       Date:  2010-07-15       Impact factor: 3.405

Review 4.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

5.  Novel bioactivity of NHERF1 in corneal neovascularization.

Authors:  Peng Chen; Ye Wang; Lingling Yang; Changyou Li; Yao Wang; Lixin Xie; Yiqiang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-10       Impact factor: 3.117

Review 6.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

7.  Role of MMP2 and MMP9 in TRPV4-induced lung injury.

Authors:  Patricia C Villalta; Petra Rocic; Mary I Townsley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-22       Impact factor: 5.464

8.  IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

Authors:  Poonam Kothari; Roberto Pestana; Rim Mesraoua; Rim Elchaki; K M Faisal Khan; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

9.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 10.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.